Accelerating Treg Therapy Manufacturing

A group of industry experts and scientific pioneers wanted to bring an entirely new approach to the treatment of autoimmune disease and needed to develop a robust regulatory T cell (Treg) manufacturing process to support clinical development needs for a Treg cell therapy product with tissue-specific activation. The sponsor sought a strategic partner who could help accelerate the manufacturing development of Abata’s Treg cell therapies by offering high-quality process and analytical development, manufacturing capabilities, and technical expertise.

ElevateBio was able to serve as the sponsor’s CMC manufacturing partner from end to end. The partnership and strategy were capital efficient, and the ability to develop a novel baseline manufacturing process in ten months shaved approximately one year off the initial IND timeline for ABA-101. Learn more about the strategies that helped accelerate the development timeline and build a process to isolate, engineer, and expand mature, thymic Tregs.